journal
MENU ▼
Read by QxMD icon Read
search

Current Vascular Pharmacology

journal
https://www.readbyqxmd.com/read/29766812/switching-dipeptidyl-peptidase-4-inhibitors-to-tofogliflozin-a-selective-inhibitor-of-sodium-glucose-cotransporter-2-improves-arterial-stiffness-evaluated-by-cardio-ankle-vascular-index-in-patients-with-type-2-diabetes
#1
Nobuhiro Tahara, Sho-Ichi Yamagish, Munehisa Bekki, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto
BACKGROUND: We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4) significantly ameliorates arterial stiffness in type 2 diabetes mellitus (T2DM) patients compared with an equivalent hypoglycemic agent, glimepiride. However, it remains unclear whether and how switching DPP-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) improves arterial stiffness in T2DM patients. METHODS: Nineteen T2DM patients who had received DPP-4 inhibitors for at least 1 year were enrolled in this study...
May 15, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29542414/clinical-presentation-quality-of-care-risk-factors-and-outcomes-in-women-with-acute-st-elevation-myocardial-infarction-stemi-an-observational-report-from-six-middle-eastern-countries
#2
Abdulla Shehab, Khalid F AlHabib, Akshaya Srikanth Bhagavathul, Ahmad Hersi, Hussam Alfaleh, Mostafa Q Alshamiri, Anhar Ullah, Khadim Sulaiman, Wael Almahmeed, Jassim Al Suwaidi, Alwai A Alsheikh-Ali, Haitham Amin, Mohammed Al Jarallah, Amar M Salam
BACKGROUND: Most of the available literature on ST-Elevated myocardial infarction (STEMI) in women was conducted in the developed world and data from Middle-East countries was limited. AIM: To examine the clinical presentation, patient management, quality of care, risk factors and in-hospital outcomes of women with acute STEMI compared with men using data from a large STEMI registry from the Middle East. METHODS: Data were derived from the third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps), a prospective, multinational study of adults with acute STEMI from 36 hospitals in 6 Middle-Eastern countries...
March 14, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29532758/platelet-derived-exosomes-affect-the-proliferation-and-migration-of-human-umbilical-vein-endothelial-cells-via-mir-126
#3
Yan Sun, Xiao-Li Liu, Dai Zhang, Fang Liu, Yu-Jing Cheng, Yue Ma, Yu-Jie Zhou, Ying-Xin Zhao
BACKGROUND: Intraplaque angiogenesis, the process of generating new blood vessels mediated by endothelial cells, contributes to plaque growth, intraplaque hemorrhage, and thromboembolic events. Platelet-derived exosomes (PLT-EXOs) affect angiogenesis in multiple ways. The ability of miR-126, one of the best-characterized miRNAs that regulates angiogenesis, carried by PLT-EXOs to influence angiogenesis via the regulation of the proliferation and migration of endothelial cells is unknown...
March 13, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29512468/effects-of-intensive-blood-pressure-control-in-patients-with-evident-cardiovascular-disease-an-investigation-using-the-sprint-study-data
#4
Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, Konstantinos Aznaouridis, Nikolaos Ioakeimidis, Panos Xaplanteris, Georgios Lazaros, Dimitrios Tousoulis
BACKGROUND: Recent data advocate adoption of a more intensive treatment strategy for management of blood pressure (BP). OBJECTIVE: We investigated whether the overall effects of the Systolic Blood Pressure Intervention Trial (SPRINT) are applicable to cardiovascular disease (CVD) patients. METHOD: In a post-hoc analysis we analyzed data from SPRINT that randomly assigned 9361 individuals to a systolic BP (SBP) target of <120 mmHg (intensive treatment) or <140 mmHg (standard treatment)...
March 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29493455/effects-of-estrogen-in-gender-dependent-fetal-programming-of-adult-cardiovascular-dysfunction
#5
Zewen Chen, Lei Wang, Jun Ke, DaLiao Xiao
BACKGROUND: Epidemiological studies and experimental studies have demonstrated that intrauterine adverse environment increases the risk of cardiovascular disease (CVD) in adulthood. However, whether an individual develops a cardiovascular dysfunctional phenotype may depend on genetic background, age, and sex. METHODS: In this review, we summarize some of the recent experimental animal studies in the developmental programming of adult CVD with an emphasis on sex differences and the potential role of estrogen in mediating sexual dimorphism...
March 1, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29437011/involvement-of-pi3k-akt-and-rhoa-in-oestradiol-regulation-of-cardiac-inos-expression
#6
Sonja Zafirovic, Emina Sudar-Milovanovic, Milan Obradovic, Jelena Djordjevic, Nebojsa Jasnic, Milica Labudovic Borovic, Esma R Isenovic
BACKGROUND: Oestradiol is an important regulatory factor with several positive effects on the cardiovascular (CV) system. We evaluated the molecular mechanism of the in vivo effects of oestradiol on the regulation of cardiac inducible nitric oxide (NO) synthase (iNOS) expression and activity. METHODS: Male Wistar rats were treated with oestradiol (40 mg/kg, intraperitoneally) and after 24 h the animals were sacrificed. The concentrations of NO and L-Arginine (L-Arg) were determined spectrophotometrically...
February 12, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29424318/the-significance-of-pain-in-chronic-venous-disease-and-its-medical-treatment
#7
Djordje Radak, Igor Atanasijevic, Mihailo Neskovic, Esma Isenovic
Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies...
February 8, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29424317/novel-hypolipidaemic-drugs-mechanisms-of-action-and-main-metabolic-effects
#8
Theodosios D Filippatos, Angelos Liontos, Eliza C Christopoulou, Moses S Elisaf
Over the last 3 decades, hypolipidaemic treatment has significantly reduced both cardiovascular (CV) risk and events, with statins being the cornerstone of this achievement. Nevertheless, residual CV risk and unmet goals in hypolipidaemic treatment make novel options necessary. Recently marketed monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have shown the way towards innovation, while other ways of PCSK9 inhibition like small interfering RNA (Inclisiran) are already being tested...
February 8, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29424316/anti-angiogenic-activity-of-curcumin-in-cancer-therapy-a-narrative-review
#9
Abolfazl Shakeri, Natalie Ward, Yunes Panahi, Amirhossein Sahebkar
Curcumin is a naturally occurring polyphenol isolated from Curcuma longa that has various pharmacological activities, including, anti-inflammatory, anti-oxidant and anti-cancer properties. The anticancer effect of curcumin is attributed to activation of apoptotic pathways in cancer cells, as well as inhibition of inflammation and angiogenesis in the tumour microenvironment and suppression of tumour metastasis. Angiogenesis, which is the formation of new blood vessels from pre-existing ones, is a fundamental step in tumour growth and expansion...
February 8, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412116/prevention-of-vascular-complications-in-diabetes-mellitus-patients-focus-on-the-arterial-wall
#10
Mojca Lunder, Miodrag Janic, Miso Sabovic
In diabetes mellitus (DM), hyperglycaemia and insulin resistance progressively lead to both microvascular and macrovascular complications. Whereas the incidence of microvascular complications is closely related to tight glycaemic control, this does not apply to macrovascular complications. Hyperglycaemia influences many interweaving molecular pathways that initially lead to increased oxidative stress, increased inflammation and endothelial dysfunction. The latter represents the initial in both types of vascular complications; it represents the "obligatory damage" in microvascular complications development and only "introductory damage" in macrovascular complications development...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412115/genetic-variations-and-subclinical-markers-of-carotid-atherosclerosis-in-patients-with-type-2-diabetes-mellitus
#11
Sara Mankoc Ramus, Danijel Petrovic
Atherosclerosis and its cardiovascular complications are the main cause of death in diabetic patients. Patients with diabetes mellitus have a greater than 10-fold risk of cardiovascular disease in their lifetime. The carotid intima-media thickness (cIMT), a surrogate marker for the presence and progression of atherosclerosis, predicts future cardiovascular events in asymptomatic subjects with type 2 diabetes mellitus (T2DM). This review focuses on genetic variants that contribute to the pathobiology of subclinical atherosclerosis in the setting of T2DM...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412114/caveolin-1-in-stroke-neuropathology-and-neuroprotection-a-novel-molecular-therapeutic-target-for-ischemic-related-injury
#12
Shanshan Wang, Brian P Head
Cardiovascular disease and associated cerebral stroke are a global epidemic attributed to genetic and epigenetic factors, such as diet, life style and an increasingly sedentary existence due to technological advances in both the developing and developed world. There are approximately 5.9 million stroke-related deaths worldwide annually. Current epidemiological data indicate that nearly 16.9 million people worldwide suffer a new or recurrent stroke yearly. In 2014 alone, 2.4% of adults in the United States (U...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412113/screening-for-rare-genetic-variants-associated-with-atherosclerosis-opportunity-for-personalized-medicine
#13
Ana Peterlin, Danijel Petrovic, Borut Peterlin
Atherosclerosis and its clinical manifestations is a leading cause of disease burden worldwide. Currently, most of the individuals carrying a strong predisposition to complications of atherosclerosis because of monogenic dyslipidaemias remain undiagnosed and consequently are not given an opportunity for prevention. Therefore, one of the main public health challenges remains the identification of individuals with significantly increased risk for atherosclerosis due to monogenic predisposition. Next-generation sequencing (NGS) has revolutionized genetic testing in symptomatic patients...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412112/novel-direct-anticoagulants-and-atherosclerosis
#14
Fabjan Andrej, Bajrovic F Fajko
Coagulation factors can affect cellular processes that include inflammatory signaling by acting on endothelial protease activated receptors, vascular smooth muscle and inflammatory cells beyond the coagulation cascade. This is important in the pathogenesis of atherosclerosis. Accordingly, experimental data points to beneficial effects of coagulation protease inhibitors on the attenuation of atherosclerosis progression in animal models. However, available clinical data do not support the use of anticoagulants as an add-on treatment of atherosclerosis...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29412111/efficacy-of-p2y12-receptor-blockers-after-myocardial-infarction-and-genetic-variability-of-their-metabolic-pathways
#15
Jan Machal, Ota Hlinomaz
BACKGROUND: Various antiplatelet drugs are used following acute coronary syndromes (ACS). Of them, adenosine diphosphate receptor P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor are currently used for post-ACS long-term treatment. Although they act on the same receptor, they differ in pharmacodynamics and pharmacokinetics. Several enzymes and transporters involved in the metabolism of P2Y12 inhibitors show genetic variability with functional impact. This includes P-glycoprotein, carboxylesterase 1 and, most notably, CYP2C19 that is important in clopidogrel activation...
February 5, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29210655/editorial-recent-news-on-statins-for-the-treatment-of-non-alcoholic-fatty-liver-disease-non-alcoholic-steatohepatitis
#16
EDITORIAL
Vasilios G Athyros, Niki Katsiki, Michael Doumas
No abstract text is available yet for this article.
January 26, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28828980/single-pill-triple-fixed-dose-combination-therapy-with-single-component-drug-monitoring-in-treatment-resistant-hypertension-a-pilot-study
#17
Reinhold Kreutz, Jurgen Scholze, Antonios Douros
BACKGROUND: Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE: This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. METHOD: The study population included patients with suspected treatment-resistant hypertension during treatment with at least 3 antihypertensive drugs...
January 26, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676023/vascular-endothelial-growth-factor-inhibitor-therapy-and-cardiovascular-and-renal-damage-in-renal-cell-carcinoma
#18
Silvia Lai, Alessio Molfino, Patrizia Seminara, Flavia Longo, Georgie Innico, Bettina Coppola, Daniela Mastroluca, Alessandro Galani, Mira Dimko, Paola Aceto, Carlo Lai
BACKGROUND: Sunitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF), is approved for first and second line treatment of advanced renal cell carcinoma (RCC). Knowledge on the effects of sunitinib on cardiovascular (CV) risk and renal damage is limited. AIM: To evaluate possible renal and CV damage in patients with RCC treated with sunitinib. MATERIALS AND METHODS: Patients with metastatic RCC treated with sunitinib were enrolled...
January 26, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28595561/sexual-dysfunction-cardiovascular-risk-and-effects-of-pharmacotherapy
#19
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Konstantinos Tziomalos, Asterios Karagiannis, Vasilios G Athyros
BACKGROUND: Sexual dysfunction affects millions of people with an increasing prevalence, worldwide. The pathophysiology of the disease shares several similarities with cardiovascular disease (CVD), including atherosclerosis, endothelial dysfunction, structural vascular damage and subclinical inflammation. Erectile dysfunction (ED) and female sexual dysfunction are common among patients with CVD and risk factors such as hypertension, diabetes, obesity and metabolic syndrome. Given the common pathogenesis of the diseases, ED is an independent prognostic factor of future ED events...
January 26, 2018: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28464775/renoprotection-by-direct-renin-inhibition-a-systematic-review-and-meta-analysis
#20
Nikolaos Louvis, James Coulson
Even mild abnormalities of the renal structure or function can increase the risk of mortality and complications in other organs. Therefore, safe and effective treatments are necessary in order to influence the progression of renal disease. We used 2 methods to assess the renoprotective effects of aliskiren: 1) a statistical analysis of clinical trials that investigated aliskiren-induced renoprotection, in terms of changes in serum creatinine concentration (sCr) or estimated glomerular filtration rate (eGFR), and, 2) clinical trials that investigated the renoprotective effects of aliskiren with respect to changes in albuminuria or proteinuria...
January 26, 2018: Current Vascular Pharmacology
journal
journal
40308
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"